PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35321823-1	2022	BACKGROUND: The THEMIS trial demonstrated that in high-risk patients with stable coronary artery disease and diabetes without previous myocardial infarction or stroke, ticagrelor, in addition to aspirin, reduced the incidence of ischemic events but increased major bleeding.	Ticagrelor	168-178	thymocyte selection associated	Homo sapiens	16-22	
33558152-1	2021	AIMS: THEMIS (NCT01991795) demonstrated cardioprotective benefits of ticagrelor plus acetylsalicylic acid (ASA) compared with placebo plus ASA in patients with type 2 diabetes (T2D), stable coronary artery disease (CAD) and no history of myocardial infarction (MI) or stroke.	Ticagrelor	69-79	thymocyte selection associated	Homo sapiens	6-12	
32662726-5	2020	EXPERT OPINION: The results of the THEMIS trial, conducted in DM patients with stable coronary artery disease and no prior stroke or myocardial infarction, showed that although ticagrelor in addition to aspirin reduced the risk of ischemic events, this was associated with a parallel increase in bleeding complications.	Ticagrelor	177-187	thymocyte selection associated	Homo sapiens	35-41	
30788847-3	2019	The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS, NCT01991795) is a Phase 3b randomized, double-blinded, placebo-controlled trial of ticagrelor vs placebo, on top of low dose aspirin.	Ticagrelor	14-24	thymocyte selection associated	Homo sapiens	94-100	
34814698-0	2021	Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial.	Ticagrelor	66-76	thymocyte selection associated	Homo sapiens	84-90	
34424771-0	2021	Applying Decision Analysis to Inform the US Food and Drug Administration"s Benefit-Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS.	Ticagrelor	102-112	thymocyte selection associated	Homo sapiens	180-186	
33985681-10	2021	CONCLUSION: Ticagrelor plus aspirin yielded generally consistent and favorable net clinical benefit across the diabetes-related factors in THEMIS-PCI but not in the overall THEMIS population.	Ticagrelor	12-22	thymocyte selection associated	Homo sapiens	139-145	
32704557-1	2020	Background: THEMIS (NCT01991795) showed that in patients with type 2 diabetes (T2D) and stable coronary artery disease (CAD) but with no prior myocardial infarction (MI) or stroke, ticagrelor plus acetylsalicylic acid (ASA) decreased the incidence of ischaemic cardiovascular events compared with placebo plus ASA.	Ticagrelor	181-191	thymocyte selection associated	Homo sapiens	12-18